Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Germany / NCT04255966
Active, not recruiting Observational

Plasmafit® Revision Structan® Hip Endoprosthesis Cup

NCT04255966 · tracked via the Priya Life Science Germany tracker
Sponsor
Aesculap AG
Phase
Observational
Started
2021-04-12
Last updated
2026-05-06

Condition(s) studied

OsteolysisArthroplasty ComplicationsInstability of Prosthetic JointDegenerative OsteoarthritisRheumatic ArthritisFractures, HipFemoral Head Avascular NecrosisProsthesis Failure

Investigational drug(s) / intervention(s)

Plasmafit® Revision Structan®

Plasmafit® Revision Structan®: Plasmafit® Revision Structan® Hip Endoprosthesis Cup

Study summary

The aim of this observational study is to collect clinical and radiological results of the new Plasmafit® Revision Structan® Hip Endoprosthesis Cup in a standard patient population and when used in routine clinical practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Indication for the cementless Plasmafit® Revision Structan® Hip Endoprosthesis Cup (primary and revision cases, with bone conditions typically demanding a press-fit revision cup) * Written informed consent * Cases where a press-fit cup fixation is possible Exclusion Criteria * Patients \< 18 years * Pregnant patients * Patients not able to comply with the study demands, i.e. follow-up visits (mentally or physically) * Patient has an infection in the hip joint region

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Orthopädische Klinik König-Ludwig-Haus Würzburg Bavaria
Herzogin Elisabeth Hospital Braunschweig Niedersachse
Gemeinschaftskrankenhaus Bonn Bonn North Rhine-Westphalia
Universitätsklinikum des Saarlandes Homburg Saarland

More Aesculap AG trials in Germany

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy Recruiting
Clinical Outcome and Fusion Rate of 3D Printed Interbody Fusion Cages and Titanium Coated PEEK Cages Active, not recruiting
Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical Recruiting
Longterm-Evaluation of Vitelene® Against Standard Active, not recruiting
DEXA Bone Density Analysis of the CoreHip® Prosthesis System Starting soon

Other trials for the same condition

Clinical and Functional Outcome of the MobileLink Acetabular Cup System in the Short-, Mid-, and Longterm Follow-up Recruiting
CoreHip - Post Market Clinical Follow-Up Study Active, not recruiting
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04255966 on ClinicalTrials.gov ↗ ← All trials in Germany